Highlights

12-19 Grifols Wins US FDA Approval for Rare Blood Disorder Drug Fesilty MT
12-19 Grifols gets FDA approval for new fibrinogen concentrate, Fesiltytm RE
12-19 Biotest AG Announces US FDA Approval of Grifols' Fesilty?? (fibrinogen, Human-Chmt) CI
12-16 European Medicines Agency Grants Compliance Certification for Plasma Supplied by Grifols Egypt MT
12-16 Grifols gets EMA approval for manufacture and selling of Egyptian plasma RE
11-18 Grifols gets FDA approval for Thrombate III in pediatric patients in U.S. RE
11-13 Grifols gets regulatory approval for fibrinogen concentrate in Germany RE
11-04 Rigel Pharma beats Q3 revenue estimates; lifts annual rev outlook RE
11-04 Grifols Q3 net profit 127 mln euros RE
09/10/25 Spanish court summons Gotham City founder in Grifols share price probe RE
10/08/25 Ex-dividend day for interim dividend FA
07/08/25 Spain's CNMV fines Grifols and several board members total of 1.36 mln euros RE
31/07/25 BofA Keeps Grifols at Buy as Strong Q2 Offsets Currency Headwinds MT
29/07/25 Grifols, S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
29/07/25 Grifols, S.A. Announces Interim Dividend for the Year 2025, Payable on 13 August 2025 CI
29/07/25 Grifols Q2 Adjusted EBITDA, Revenue Rise; Dividend Payment Reinstated MT
29/07/25 Grifols reaffirms 2025 guidance with improved FCF pre-M&A guidance RE
29/07/25 Grifols to pay interim dividend of 0.15 eur/shr on Aug 13 RE
29/07/25 Grifols H1 net profit at 176.8 mln euros RE
28/07/25 Astrazeneca, Other US-Listed Pharma Companies Seen Insulated From New EU Tariff Deal, Barclays Says MT
19/06/25 Grifols Says Positive Fibrinogen Phase 3 Trial Results Published RE
12/06/25 Grifols to Finalize Delisting Offer for Biotest MT
11/06/25 Grifols Says Delisting Offer Accepted By 416,922 Ordinary Shares Of Biotest RE
04/06/25 Biotest to Delist from Frankfurt Bourse MT
30/05/25 US Court Allows Grifols' Defamation Suit Against Gotham City to Proceed MT
No results for this search